Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and limitations

Journal of Clinical Oncology

Volumn 18, Issue 20, 2000, Pages 3495-3502

  Avril, N ^a   Rose C A ^a   Schelling, M ^a   Dose, J ^a   Kuhn, W ^a   Bense, S ^a   Weber, W ^a   Ziegler, S ^a   Graeff, H ^a   Schwaiger, M ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; BREAST CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL;

EID: 0034667846     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.20.3495     Document Type: Article

References (48)

1. Evaluation of a palpable breast mass
2. Report of the international workshop on screening for breast cancer
3. Detection method, tumor size and node metastases in breast cancer diagnosed during a trial of breast cancer screening
4. Mammography screening and the controversy concerning women aged 40 to 49
5. Breast masses: Mammographic evaluation
6. False positive rate of screening mammography
7. The positive predictive value of mammography
8. Biopsy of occult breast lesions: Analysis of 1261 abnormalities
9. Analysis of cancer missed at screening mammography
10. The current role of ultrasonography in breast imaging
11. Solid breast nodules: Use of sonography to distinguish between benign and malignant lesions
12. MR imaging of the breast with Gd-DTPA: Use and limitations
13. Nonpalpable breast tumors: Diagnosis with contrast-enhanced subtraction dynamic MR imaging
14. MRI of the breast: State of the art
15. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose
16. Relevance of positron emission tomography (PET) in oncology
17. On the origin of cancer cells
18. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): Nontoxic tracer for rapid tumor detection
19. Primary and metastatic breast carcinoma: Initial clinical evaluation with PET with the radiolabled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose
20. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET
21. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose
22. Efficient stereospecific synthesis of nocarrier-added 2-(F-18)-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution
23. Breast imaging with fluorine-18-FDG PET: Quantitative image analysis
24. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer
25. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease
26. Qualitative F-18 FDG positron emission tomography in primary breast cancer: Clinical relevance and practicability
27. Magnetic resonance imaging and its role in the diagnosis of multicentric breast cancer
28. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases
29. Invasive lobular carcinoma: Mammographic findings in a 10-year experience
30. Invasive lobular carcinoma of the breast: Mammographic findings and extent of disease at diagnosis in 184 patients
31. Invasive lobular carcinoma: Imaging features and clinical detection
32. Invasive lobular carcinoma: Sonographic appearance and role of sonography in improving diagnostic sensitivity
33. Tumor oxygenation correlates with molecular growth determinants in breast cancer
34. Quantitation in positron emission computed tomography: 1. Effect of object size
35. Untreated primary lung and breast cancers: Correlation between F-18 FDG kinetic rate constants and findings of in vitro studies
36. High [18-F]-fluorodeoxyglucose uptake in abdominal abscesses: A PET study
37. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis
38. Nonpalpable breast lesions: Findings of stereotaxic needle-core biopsy and fine needle aspiration cytology
39. Utility of PET in breast cancer
40. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose
41. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma
42. Value of F-18 fluorodeoxyglucose positron emission tomography in the staging of recurrent breast carcinoma
43. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation
44. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: A method for early therapy evaluation?
45. Evaluation of preoperative chemotherapy using PET with fluorine-18- fluorodeoxyglucose in breast cancer
46. Positron emission tomography using F-18 fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer